Felty syndrome is infrequent in seropositive rheumatoid arthritis, where patients exhibit RA, neutropenia, and splenomegaly. The syndrome was first identified in 1924 at Johns Hopkins Hospital by Dr. Augustus Felty, who noted a connection between chronic arthritis, splenomegaly, and leukopenia.
The term “Felty syndrome” was coined by Hanrahan and Miller in 1932 after describing a patient whose symptoms were similar to those noted by Dr. Felty. Although the presence of chronic arthritis, splenomegaly, and neutropenia is commonly observed in Felty syndrome, it is not required to establish a diagnosis. However, neutropenia is a defining feature of the syndrome and must be present.
Epidemiology
Felty syndrome is a rare complication of rheumatoid arthritis (RA), and its exact prevalence is unknown. Studies suggest that it affects less than 1% of people with RA, typically those who have had RA for at least 10 years. The condition is more commonly observed in individuals who are older, Caucasian, and have a longer duration of RA.
Women are affected more frequently than men, with a female-to-male ratio of approximately 3:1. Felty syndrome is rare in children and young adults and is more commonly diagnosed in individuals over 50. The incidence of Felty syndrome appears to be decreasing in recent years, possibly due to the earlier diagnosis and more effective treatment of RA.
Anatomy
Pathophysiology
The pathophysiology of Felty syndrome is not fully understood, but it is believed to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder that results in chronic inflammation and joint destruction. The exact mechanism by which Felty syndrome develops is not clear, but it is thought to be related to the production of autoantibodies that target white blood cells, leading to their destruction and a decrease in the number of circulating neutrophils.
This decrease in neutrophils is known as neutropenia, a hallmark feature of Felty syndrome. In addition to neutropenia, people with Felty syndrome may have other immune system abnormalities, such as an increase in circulating immune complexes and a decrease in complement activity.
These abnormalities may contribute to the development of the syndrome and its associated complications. The enlarged spleen observed in Felty syndrome is thought to be due to the accumulation of immune complexes and white blood cells in the spleen and the destruction of white blood cells by autoantibodies.
The spleen plays an important role in filtering the blood and removing damaged or abnormal cells, and its enlargement can reduce the number of circulating red and white blood cells. The chronic inflammation observed in RA and Felty syndrome can also contribute to the development of complications, such as joint damage, inflammation of the blood vessels, and an increased risk of infections.
Etiology
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
Genetics
Prognostic Factors
The prognosis of Felty syndrome can vary depending on the severity of the disease and the presence of associated complications. In general, the prognosis is worse for patients with more severe joint involvement, high disease activity, and recurrent infections.
With appropriate management of rheumatoid arthritis, neutropenia, and associated complications, many patients with Felty syndrome are able to achieve good disease control and improve their quality of life. However, some patients may experience persistent joint inflammation, recurrent infections, and disease-related complications despite treatment.
The risk of mortality is higher in patients with Felty syndrome compared to patients with rheumatoid arthritis without neutropenia. The leading causes of mortality in Felty syndrome are infections and complications related to neutropenia. Regular monitoring for infections and prompt management of infections is important for improving the prognosis in these patients. Overall, the prognosis of Felty syndrome can be improved with appropriate and timely treatment, close monitoring, and multidisciplinary care.
Clinical History
Clinical history
The clinical history of Felty syndrome typically includes:
Rheumatoid arthritis: Patients with Felty syndrome usually have a long-standing history of rheumatoid arthritis, a chronic autoimmune disorder characterized by joint inflammation, pain, and stiffness.
Neutropenia: Felty syndrome is defined by the presence of neutropenia, a condition where the number of neutrophils (a type of white blood cell) in the blood is lower than normal. Neutropenia can increase the risk of infections.
Splenomegaly: An enlarged spleen is a common feature of Felty syndrome and may cause discomfort in the left upper quadrant of the abdomen.
Constitutional symptoms: Patients with Felty syndrome may experience fatigue, weight loss, and fever.
Skin changes: Some patients with Felty syndrome may develop skin lesions, such as ulcers, nodules, or purpura.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may occur in some patients.
Previous treatments: Patients with Felty syndrome may have a history of treatment with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for rheumatoid arthritis.
The clinical presentation of Felty syndrome can vary widely, and not all patients may exhibit all of the above features. The diagnosis of Felty syndrome is usually made based on the combination of clinical features, laboratory tests, and imaging studies.
Physical Examination
Physical examination
The physical examination of a patient with Felty syndrome may reveal several clinical features, including:
Rheumatoid arthritis: Patients with Felty syndrome may have signs of rheumatoid arthritis, including joint swelling, tenderness, and deformities.
Splenomegaly: An enlarged spleen may be palpable in the left upper quadrant of the abdomen.
Neutropenia: A low white blood cell count may be detected on a complete blood count (CBC) test. This may lead to an increased risk of infections.
Skin changes: Skin lesions, such as ulcers, nodules, or purpura, may be present in some patients with Felty syndrome.
Lymphadenopathy: Enlarged lymph nodes may be present in some patients.
Hepatomegaly: An enlarged liver may be detected on physical examination.
Constitutional symptoms: Patients with Felty syndrome may experience fever, fatigue, and weight loss.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may be present in some patients.
Overall, the physical examination findings in Felty syndrome are often nonspecific and may overlap with those of other diseases. The diagnosis of Felty syndrome is typically based on a combination of clinical features, including rheumatoid arthritis, splenomegaly, and neutropenia, along with laboratory and imaging tests.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The treatment of Felty syndrome typically involves the management of rheumatoid arthritis, neutropenia, and associated complications. The goals of treatment are to control joint inflammation, prevent infections, and improve quality of life. The specific treatment approach may vary depending on the severity of symptoms, the presence of other medical conditions, and the patient’s overall health status.
Rheumatoid arthritis: The management of rheumatoid arthritis in Felty syndrome typically involves using disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, sulfasalazine, or leflunomide, to control joint inflammation and prevent joint damage. Biologic agents, such as tumor necrosis factor (TNF) inhibitors, may be used in patients with more severe disease.
Neutropenia: Patients with Felty syndrome who have neutropenia may require treatment with granulocyte colony-stimulating factor (G-CSF) to increase neutrophil counts and reduce the risk of infections. In some cases, splenectomy (surgical removal of the spleen) may improve neutropenia and reduce the risk of infections.
Infections: Patients with Felty syndrome are at increased risk of infections due to neutropenia and impaired immune function. Appropriate measures should be taken to prevent infections, such as immunizations and prophylactic antibiotics.
Supportive care: Patients with Felty syndrome may require supportive care to manage associated complications, such as anemia, thrombocytopenia, and skin ulcers. This may include blood transfusions, iron supplements, and wound care.
Lifestyle modifications: Patients with Felty syndrome may benefit from lifestyle modifications, such as regular exercise, weight management, and smoking cessation, to improve overall health and reduce the risk of complications.
The management of Felty syndrome requires a multidisciplinary approach involving rheumatologists, hematologists, and infectious disease specialists. The treatment approach should be tailored to the individual patient’s needs and may involve a combination of pharmacologic and non-pharmacologic interventions.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK546693/
News
Rare Uterine Lipoma Diagnosed Post-Surgery: Case Report
Posted on
News
Robotic Breakthrough in Brain Surgery
Posted on
News
Bangladesh Achieves Remarkable Reduction in Lead in Turmeric
Posted on
News
Suppressing Negative Thoughts Can Improve Mental Health
Felty syndrome is infrequent in seropositive rheumatoid arthritis, where patients exhibit RA, neutropenia, and splenomegaly. The syndrome was first identified in 1924 at Johns Hopkins Hospital by Dr. Augustus Felty, who noted a connection between chronic arthritis, splenomegaly, and leukopenia.
The term “Felty syndrome” was coined by Hanrahan and Miller in 1932 after describing a patient whose symptoms were similar to those noted by Dr. Felty. Although the presence of chronic arthritis, splenomegaly, and neutropenia is commonly observed in Felty syndrome, it is not required to establish a diagnosis. However, neutropenia is a defining feature of the syndrome and must be present.
Felty syndrome is a rare complication of rheumatoid arthritis (RA), and its exact prevalence is unknown. Studies suggest that it affects less than 1% of people with RA, typically those who have had RA for at least 10 years. The condition is more commonly observed in individuals who are older, Caucasian, and have a longer duration of RA.
Women are affected more frequently than men, with a female-to-male ratio of approximately 3:1. Felty syndrome is rare in children and young adults and is more commonly diagnosed in individuals over 50. The incidence of Felty syndrome appears to be decreasing in recent years, possibly due to the earlier diagnosis and more effective treatment of RA.
The pathophysiology of Felty syndrome is not fully understood, but it is believed to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder that results in chronic inflammation and joint destruction. The exact mechanism by which Felty syndrome develops is not clear, but it is thought to be related to the production of autoantibodies that target white blood cells, leading to their destruction and a decrease in the number of circulating neutrophils.
This decrease in neutrophils is known as neutropenia, a hallmark feature of Felty syndrome. In addition to neutropenia, people with Felty syndrome may have other immune system abnormalities, such as an increase in circulating immune complexes and a decrease in complement activity.
These abnormalities may contribute to the development of the syndrome and its associated complications. The enlarged spleen observed in Felty syndrome is thought to be due to the accumulation of immune complexes and white blood cells in the spleen and the destruction of white blood cells by autoantibodies.
The spleen plays an important role in filtering the blood and removing damaged or abnormal cells, and its enlargement can reduce the number of circulating red and white blood cells. The chronic inflammation observed in RA and Felty syndrome can also contribute to the development of complications, such as joint damage, inflammation of the blood vessels, and an increased risk of infections.
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
The prognosis of Felty syndrome can vary depending on the severity of the disease and the presence of associated complications. In general, the prognosis is worse for patients with more severe joint involvement, high disease activity, and recurrent infections.
With appropriate management of rheumatoid arthritis, neutropenia, and associated complications, many patients with Felty syndrome are able to achieve good disease control and improve their quality of life. However, some patients may experience persistent joint inflammation, recurrent infections, and disease-related complications despite treatment.
The risk of mortality is higher in patients with Felty syndrome compared to patients with rheumatoid arthritis without neutropenia. The leading causes of mortality in Felty syndrome are infections and complications related to neutropenia. Regular monitoring for infections and prompt management of infections is important for improving the prognosis in these patients. Overall, the prognosis of Felty syndrome can be improved with appropriate and timely treatment, close monitoring, and multidisciplinary care.
Clinical history
The clinical history of Felty syndrome typically includes:
Rheumatoid arthritis: Patients with Felty syndrome usually have a long-standing history of rheumatoid arthritis, a chronic autoimmune disorder characterized by joint inflammation, pain, and stiffness.
Neutropenia: Felty syndrome is defined by the presence of neutropenia, a condition where the number of neutrophils (a type of white blood cell) in the blood is lower than normal. Neutropenia can increase the risk of infections.
Splenomegaly: An enlarged spleen is a common feature of Felty syndrome and may cause discomfort in the left upper quadrant of the abdomen.
Constitutional symptoms: Patients with Felty syndrome may experience fatigue, weight loss, and fever.
Skin changes: Some patients with Felty syndrome may develop skin lesions, such as ulcers, nodules, or purpura.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may occur in some patients.
Previous treatments: Patients with Felty syndrome may have a history of treatment with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for rheumatoid arthritis.
The clinical presentation of Felty syndrome can vary widely, and not all patients may exhibit all of the above features. The diagnosis of Felty syndrome is usually made based on the combination of clinical features, laboratory tests, and imaging studies.
Physical examination
The physical examination of a patient with Felty syndrome may reveal several clinical features, including:
Rheumatoid arthritis: Patients with Felty syndrome may have signs of rheumatoid arthritis, including joint swelling, tenderness, and deformities.
Splenomegaly: An enlarged spleen may be palpable in the left upper quadrant of the abdomen.
Neutropenia: A low white blood cell count may be detected on a complete blood count (CBC) test. This may lead to an increased risk of infections.
Skin changes: Skin lesions, such as ulcers, nodules, or purpura, may be present in some patients with Felty syndrome.
Lymphadenopathy: Enlarged lymph nodes may be present in some patients.
Hepatomegaly: An enlarged liver may be detected on physical examination.
Constitutional symptoms: Patients with Felty syndrome may experience fever, fatigue, and weight loss.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may be present in some patients.
Overall, the physical examination findings in Felty syndrome are often nonspecific and may overlap with those of other diseases. The diagnosis of Felty syndrome is typically based on a combination of clinical features, including rheumatoid arthritis, splenomegaly, and neutropenia, along with laboratory and imaging tests.
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
The treatment of Felty syndrome typically involves the management of rheumatoid arthritis, neutropenia, and associated complications. The goals of treatment are to control joint inflammation, prevent infections, and improve quality of life. The specific treatment approach may vary depending on the severity of symptoms, the presence of other medical conditions, and the patient’s overall health status.
Rheumatoid arthritis: The management of rheumatoid arthritis in Felty syndrome typically involves using disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, sulfasalazine, or leflunomide, to control joint inflammation and prevent joint damage. Biologic agents, such as tumor necrosis factor (TNF) inhibitors, may be used in patients with more severe disease.
Neutropenia: Patients with Felty syndrome who have neutropenia may require treatment with granulocyte colony-stimulating factor (G-CSF) to increase neutrophil counts and reduce the risk of infections. In some cases, splenectomy (surgical removal of the spleen) may improve neutropenia and reduce the risk of infections.
Infections: Patients with Felty syndrome are at increased risk of infections due to neutropenia and impaired immune function. Appropriate measures should be taken to prevent infections, such as immunizations and prophylactic antibiotics.
Supportive care: Patients with Felty syndrome may require supportive care to manage associated complications, such as anemia, thrombocytopenia, and skin ulcers. This may include blood transfusions, iron supplements, and wound care.
Lifestyle modifications: Patients with Felty syndrome may benefit from lifestyle modifications, such as regular exercise, weight management, and smoking cessation, to improve overall health and reduce the risk of complications.
The management of Felty syndrome requires a multidisciplinary approach involving rheumatologists, hematologists, and infectious disease specialists. The treatment approach should be tailored to the individual patient’s needs and may involve a combination of pharmacologic and non-pharmacologic interventions.
https://www.ncbi.nlm.nih.gov/books/NBK546693/
medtigo
Felty syndrome
Updated :
August 17, 2023
Felty syndrome is infrequent in seropositive rheumatoid arthritis, where patients exhibit RA, neutropenia, and splenomegaly. The syndrome was first identified in 1924 at Johns Hopkins Hospital by Dr. Augustus Felty, who noted a connection between chronic arthritis, splenomegaly, and leukopenia.
The term “Felty syndrome” was coined by Hanrahan and Miller in 1932 after describing a patient whose symptoms were similar to those noted by Dr. Felty. Although the presence of chronic arthritis, splenomegaly, and neutropenia is commonly observed in Felty syndrome, it is not required to establish a diagnosis. However, neutropenia is a defining feature of the syndrome and must be present.
Felty syndrome is a rare complication of rheumatoid arthritis (RA), and its exact prevalence is unknown. Studies suggest that it affects less than 1% of people with RA, typically those who have had RA for at least 10 years. The condition is more commonly observed in individuals who are older, Caucasian, and have a longer duration of RA.
Women are affected more frequently than men, with a female-to-male ratio of approximately 3:1. Felty syndrome is rare in children and young adults and is more commonly diagnosed in individuals over 50. The incidence of Felty syndrome appears to be decreasing in recent years, possibly due to the earlier diagnosis and more effective treatment of RA.
The pathophysiology of Felty syndrome is not fully understood, but it is believed to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder that results in chronic inflammation and joint destruction. The exact mechanism by which Felty syndrome develops is not clear, but it is thought to be related to the production of autoantibodies that target white blood cells, leading to their destruction and a decrease in the number of circulating neutrophils.
This decrease in neutrophils is known as neutropenia, a hallmark feature of Felty syndrome. In addition to neutropenia, people with Felty syndrome may have other immune system abnormalities, such as an increase in circulating immune complexes and a decrease in complement activity.
These abnormalities may contribute to the development of the syndrome and its associated complications. The enlarged spleen observed in Felty syndrome is thought to be due to the accumulation of immune complexes and white blood cells in the spleen and the destruction of white blood cells by autoantibodies.
The spleen plays an important role in filtering the blood and removing damaged or abnormal cells, and its enlargement can reduce the number of circulating red and white blood cells. The chronic inflammation observed in RA and Felty syndrome can also contribute to the development of complications, such as joint damage, inflammation of the blood vessels, and an increased risk of infections.
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
The prognosis of Felty syndrome can vary depending on the severity of the disease and the presence of associated complications. In general, the prognosis is worse for patients with more severe joint involvement, high disease activity, and recurrent infections.
With appropriate management of rheumatoid arthritis, neutropenia, and associated complications, many patients with Felty syndrome are able to achieve good disease control and improve their quality of life. However, some patients may experience persistent joint inflammation, recurrent infections, and disease-related complications despite treatment.
The risk of mortality is higher in patients with Felty syndrome compared to patients with rheumatoid arthritis without neutropenia. The leading causes of mortality in Felty syndrome are infections and complications related to neutropenia. Regular monitoring for infections and prompt management of infections is important for improving the prognosis in these patients. Overall, the prognosis of Felty syndrome can be improved with appropriate and timely treatment, close monitoring, and multidisciplinary care.
Clinical history
The clinical history of Felty syndrome typically includes:
Rheumatoid arthritis: Patients with Felty syndrome usually have a long-standing history of rheumatoid arthritis, a chronic autoimmune disorder characterized by joint inflammation, pain, and stiffness.
Neutropenia: Felty syndrome is defined by the presence of neutropenia, a condition where the number of neutrophils (a type of white blood cell) in the blood is lower than normal. Neutropenia can increase the risk of infections.
Splenomegaly: An enlarged spleen is a common feature of Felty syndrome and may cause discomfort in the left upper quadrant of the abdomen.
Constitutional symptoms: Patients with Felty syndrome may experience fatigue, weight loss, and fever.
Skin changes: Some patients with Felty syndrome may develop skin lesions, such as ulcers, nodules, or purpura.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may occur in some patients.
Previous treatments: Patients with Felty syndrome may have a history of treatment with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for rheumatoid arthritis.
The clinical presentation of Felty syndrome can vary widely, and not all patients may exhibit all of the above features. The diagnosis of Felty syndrome is usually made based on the combination of clinical features, laboratory tests, and imaging studies.
Physical examination
The physical examination of a patient with Felty syndrome may reveal several clinical features, including:
Rheumatoid arthritis: Patients with Felty syndrome may have signs of rheumatoid arthritis, including joint swelling, tenderness, and deformities.
Splenomegaly: An enlarged spleen may be palpable in the left upper quadrant of the abdomen.
Neutropenia: A low white blood cell count may be detected on a complete blood count (CBC) test. This may lead to an increased risk of infections.
Skin changes: Skin lesions, such as ulcers, nodules, or purpura, may be present in some patients with Felty syndrome.
Lymphadenopathy: Enlarged lymph nodes may be present in some patients.
Hepatomegaly: An enlarged liver may be detected on physical examination.
Constitutional symptoms: Patients with Felty syndrome may experience fever, fatigue, and weight loss.
Ocular involvement: Uveitis, scleritis, or other ocular manifestations may be present in some patients.
Overall, the physical examination findings in Felty syndrome are often nonspecific and may overlap with those of other diseases. The diagnosis of Felty syndrome is typically based on a combination of clinical features, including rheumatoid arthritis, splenomegaly, and neutropenia, along with laboratory and imaging tests.
The exact cause of Felty syndrome is unknown, but it is thought to be related to the immune system dysfunction that occurs in rheumatoid arthritis (RA). RA is an autoimmune disorder in which the body’s immune system mistakenly attacks its own tissues, resulting in chronic inflammation and joint destruction.
In Felty syndrome, this immune system dysfunction also leads to the destruction of white blood cells, specifically neutrophils, which results in neutropenia. Genetic factors are thought to play a role in developing RA and Felty syndrome. Certain genetic markers, such as HLA-DR4, have been associated with an increased risk of developing RA, and some studies suggest that these markers may also increase the risk of developing Felty syndrome.
Environmental factors, such as infections or exposure to certain toxins, may also contribute to the development of RA and Felty syndrome. However, the exact role of these factors in the development of Felty syndrome is unclear. Overall, the development of Felty syndrome is likely a complex interplay between genetic and environmental factors, with immune system dysfunction and neutropenia central to the syndrome’s development.
The treatment of Felty syndrome typically involves the management of rheumatoid arthritis, neutropenia, and associated complications. The goals of treatment are to control joint inflammation, prevent infections, and improve quality of life. The specific treatment approach may vary depending on the severity of symptoms, the presence of other medical conditions, and the patient’s overall health status.
Rheumatoid arthritis: The management of rheumatoid arthritis in Felty syndrome typically involves using disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, sulfasalazine, or leflunomide, to control joint inflammation and prevent joint damage. Biologic agents, such as tumor necrosis factor (TNF) inhibitors, may be used in patients with more severe disease.
Neutropenia: Patients with Felty syndrome who have neutropenia may require treatment with granulocyte colony-stimulating factor (G-CSF) to increase neutrophil counts and reduce the risk of infections. In some cases, splenectomy (surgical removal of the spleen) may improve neutropenia and reduce the risk of infections.
Infections: Patients with Felty syndrome are at increased risk of infections due to neutropenia and impaired immune function. Appropriate measures should be taken to prevent infections, such as immunizations and prophylactic antibiotics.
Supportive care: Patients with Felty syndrome may require supportive care to manage associated complications, such as anemia, thrombocytopenia, and skin ulcers. This may include blood transfusions, iron supplements, and wound care.
Lifestyle modifications: Patients with Felty syndrome may benefit from lifestyle modifications, such as regular exercise, weight management, and smoking cessation, to improve overall health and reduce the risk of complications.
The management of Felty syndrome requires a multidisciplinary approach involving rheumatologists, hematologists, and infectious disease specialists. The treatment approach should be tailored to the individual patient’s needs and may involve a combination of pharmacologic and non-pharmacologic interventions.
https://www.ncbi.nlm.nih.gov/books/NBK546693/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
